Population Modeling of Tumor Kinetics and Overall Survival to Identify Prognostic and Predictive Biomarkers of Efficacy for Durvalumab in Patients With Urothelial Carcinoma

Durvalumab is an anti‐PD‐L1 monoclonal antibody approved for patients with locally advanced or metastatic urothelial carcinoma (UC) that has progressed after platinum‐containing chemotherapy. A population tumor kinetic model, coupled with dropout and survival models, was developed to describe longit...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Pharmacol Ther
Main Authors: Zheng, Yanan, Narwal, Rajesh, Jin, ChaoYu, Baverel, Paul G., Jin, Xiaoping, Gupta, Ashok, Ben, Yong, Wang, Bing, Mukhopadhyay, Pralay, Higgs, Brandon W., Roskos, Lorin
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2018
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5873369/
https://ncbi.nlm.nih.gov/pubmed/29243222
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpt.986
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados